Patents Issued in April 18, 2024
  • Publication number: 20240122885
    Abstract: Provided are methods of modulating gene expression levels in an individual identified as having endometriosis. The methods comprise administering to the individual identified as having endometriosis a drug described herein in an amount effective to modulate gene expression levels in the individual. Also provided are pharmaceutical compositions. The compositions comprise a drug described herein in an amount effective to modulate gene expression levels in an individual, wherein the pharmaceutical composition is adapted for intrauterine or intravaginal administration of the drug to the individual. Kits that find use in practicing the methods of the present disclosure are also provided. In some embodiments, the kits comprise a pharmaceutical composition comprising a drug described herein in an amount effective to modulate gene expression levels in the individual, and instructions for administering the pharmaceutical composition to an individual identified as having endometriosis.
    Type: Application
    Filed: February 11, 2022
    Publication date: April 18, 2024
    Inventors: Marina Sirota, Linda Giudice, Arohee Bhoja, Daniel Bunis
  • Publication number: 20240122886
    Abstract: Provided in some embodiments are methods of treating or preventing Raynaud's, comprising prescribing and/or administering to an individual in need thereof 2-(((1r,4r)-4-(((4-chlorophenyl)(phenyl)carbamoyloxy)methyl)cyclohexyl)methoxy)acetic acid (Compound 1), or a pharmaceutically acceptable salt, hydrate, or solvate thereof.
    Type: Application
    Filed: June 14, 2023
    Publication date: April 18, 2024
    Inventors: John W. ADAMS, Christen M. ANDERSON, William R. SHANAHAN
  • Publication number: 20240122887
    Abstract: Pharmaceutical compositions comprising L-4-chlorokynurenine and associated therapeutic methods are provided for the treatment of certain neurological and other conditions.
    Type: Application
    Filed: September 30, 2022
    Publication date: April 18, 2024
    Applicant: VISTAGEN THERAPEUTICS, INC.
    Inventor: H. Ralph SNODGRASS
  • Publication number: 20240122888
    Abstract: The present disclosure generally relates to systems and methods for delivering lactate and phenylalanine, and/or N-lactoyl-phenylalanine and/or other N-lactoyl amino acids to a subject. In some cases, these may be used for appetite control, weight loss, treating or preventing obesity, or for other metabolic-related diseases. In addition, certain embodiments are generally directed to treatments that can be delivered using topical compositions applied to the skin. For example, in some cases, the composition includes lecithin and/or other components that may facilitate delivery through the skin. Further, certain embodiments may include active ingredients such as tributyrin or 2,6-dimethyl-L-tyrosine, which may interact with lactate and phenylalanine, and/or N-lactoyl-phenylalanine and/or other N-lactoyl amino acids. Compositions such as these may be used in certain embodiments, for example, to suppress a subject's appetite, etc.
    Type: Application
    Filed: March 2, 2023
    Publication date: April 18, 2024
    Applicant: Transdermal Biotechnology, Inc.
    Inventor: Nicholas V. Perricone
  • Publication number: 20240122889
    Abstract: The present disclosure provides dry powder compositions of treprostinil prodrugs and methods of treating pulmonary hypertension (e.g., pulmonary arterial hypertension or PH associated with interstitial lung disease), in a patient in need thereof with the same. The dry powder composition includes (a) from about 0.5 wt % to about 5 wt % of a compound of Formula (I): a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, (b) from about 10 wt % to about 61 wt % of leucine, and the balance being (c) a sugar selected from the group consisting of trehalose and mannitol. The entirety of (a), (b), and (c) is 100 wt %, and R1 is tetradecyl, pentadecyl, hexadecyl, heptadecyl, or octadecyl. The method of treating PH includes administering an effective amount of the dry powder composition to the lungs of the patient by inhalation via a dry powder inhaler, during an administration period. In certain compositions and methods provided herein, R1 is hexadecyl, e.g., linear hexadecyl.
    Type: Application
    Filed: November 17, 2023
    Publication date: April 18, 2024
    Inventors: Gerald O’Brien, Fraz Ismat, Ariel Teper
  • Publication number: 20240122890
    Abstract: In various embodiments method and compositions are provided for inducing weight loss in a mammal. In certain embodiments the methods involve administering to a mammal an effective amount of a fatty acid ?-hydroxyester compounds and/or one or more esters of butanediol.
    Type: Application
    Filed: January 24, 2022
    Publication date: April 18, 2024
    Applicant: Buck Institute for Research on Aging
    Inventors: John C. Newman, Brianna J. Stubbs
  • Publication number: 20240122891
    Abstract: Suggested is a cosmetic or pharmaceutical composition comprising (a) at least one alkanediol ester of carboxylic acids as antimicrobial agent, wherein the carboxylic acids contain 6 to 12 C atoms; (b) at least one emulsifier; (c) water; (d) and at least one antimicrobial agent.
    Type: Application
    Filed: November 6, 2019
    Publication date: April 18, 2024
    Inventors: Ravikumar PILLAI, Lars JUNG, Martina KÖNIG
  • Publication number: 20240122892
    Abstract: The present invention relates to diffusers for dogs and cats, containing formulations capable of passively diffusing semiochemical compositions.
    Type: Application
    Filed: February 1, 2022
    Publication date: April 18, 2024
    Applicant: VIRBAC
    Inventors: Aurélie Girardin, Patricia Monginoux, Vitor Manuel Da Silva Pinto, Vera Mónica Ramos Da Silva Raínho, Cátia Filipa Mendes Rodrigues, Cindy Novo de Carvalho, Maria Helena Machado Parrula Silva
  • Publication number: 20240122893
    Abstract: Disclosed herein, are methods for treating, preventing or inhibiting a coronavirus infection or a disease or condition associated with a coronavirus infection. The methods can comprise administering to the subject one or more therapeutically effective doses of sulforaphane.
    Type: Application
    Filed: February 23, 2022
    Publication date: April 18, 2024
    Inventors: Lorraine V. Brando, Alvaro A. Ordonez, Robert H. Yolken, Sanjay K. Jain
  • Publication number: 20240122894
    Abstract: Provided is a method for coupling flavonoid-containing compounds to provide flavonoid dimers, trimers and oligomers. The method comprises contacting a flavonoid-containing compound with base in the presence of air. Flavonoid dimers, trimers and oligomers may also be useful in the treatment of diseases, such as fungal infections and diseases associated with starch hydrolase.
    Type: Application
    Filed: December 10, 2021
    Publication date: April 18, 2024
    Applicant: National University of Singapore
    Inventors: Xin Yang, Dejian Huang, Ke Du, Yi Hui Joanne Toy
  • Publication number: 20240122895
    Abstract: Provided are methods of administering an entactogen in conjunction with psychotherapy to treat a condition and/or to treat one or more comorbidities in a subject. In other aspects, provided are compositions, such as pharmaceutical compositions, comprising an entactogen for use in an entactogen-assisted psychotherapy (EAP) regimen. In some embodiments, the entactogen is MDMA, for use in MDMA-assisted therapy. In some aspects, the provided EAP methods are used to treat a substance use disorder (SUD) or a behavioral addiction. In some embodiments, the SUD is alcohol use disorder (AUD), including physically dependent (“dependent use”) AUD or non-physically dependent (“harmful use”) AUD. In a further aspect, the provided EAP methods are used to treat one or more of a comorbid SUD, behavioral addiction, or mental health disorder.
    Type: Application
    Filed: July 6, 2023
    Publication date: April 18, 2024
    Inventors: Ben Sessa, Laurie Higbed, David Nutt
  • Publication number: 20240122896
    Abstract: Methods for reducing the progression of ER+breast cancer in a patient are provided, the methods comprising administering to the patient an effective amount of lasofoxifene or a pharmaceutically acceptable salt thereof and an effective amount of a CDK4/6 inhibitor (CDK4/6i), wherein the breast cancer: (i) is estrogen receptor positive (ER+); (ii) has at least one gain of function missense mutation within the ligand binding domain (LBD) of the Estrogen Receptor 1 (ESR1) gene; and (iii) has progressed during prior CDK4/6 inhibitor therapy and/or has an oncogenic mutation in a gene other than ESR1.
    Type: Application
    Filed: December 5, 2023
    Publication date: April 18, 2024
    Inventors: David J. PORTMAN, Paul PLOURDE, Simon JENKINS
  • Publication number: 20240122897
    Abstract: DMT nicotinate and DMT pamoate are disclosed. DMT and its salts are found useful in the treatment of stroke, multiple sclerosis, Parkinson's disease, and traumatic brain injury. They are particularly useful in the treatment of haemorrhagic stroke. They are particularly useful in the immediate treatment of undiagnosed stroke. They are for use with anti-hypertensives when treating haemorrhagic stroke or TBI. Also taught are preferred dosages and serum levels of DMT, an intravenous pump device containing a pharmaceutically acceptable form of DMT. The pump may be configured to provide a specific dose and/or duration. The pump may have a locking system to prevent access to said compound or said DMT above the dose.
    Type: Application
    Filed: January 28, 2022
    Publication date: April 18, 2024
    Inventors: Mark WILLIAMS, Christopher BRYAN
  • Publication number: 20240122898
    Abstract: The present invention provides a patch comprising an adhesive layer on a backing, the adhesive layer comprising: asenapine or a pharmaceutically acceptable salt thereof; an adhesive base; and at least one selected from the group consisting of thiosulfates, sulfites, and pyrosulfites.
    Type: Application
    Filed: October 19, 2020
    Publication date: April 18, 2024
    Inventors: Yuka TAKAGI, Masaki YUKUHIRO
  • Publication number: 20240122899
    Abstract: The present invention aims to provide a composition for promoting immune cell metabolism, a composition for activating immunity, a method of promoting immune cell metabolism, and a method of activating immunity. The present invention relates to a composition for promoting immune cell metabolism, which contains L-ergothioneine or a salt thereof as an active ingredient.
    Type: Application
    Filed: March 25, 2022
    Publication date: April 18, 2024
    Applicant: SUNTORY HOLDINGS LIMITED
    Inventors: Makoto Katsube, Hiroshi Watanabe, Mariko Ozawa
  • Publication number: 20240122900
    Abstract: The present invention provides methods, compositions (e.g., eyedrop or spongarion composition), and uses for alleviating and preventing age-associated vitreous degeneration in a mammal, comprising administrating to the mammal in need thereof a therapeutically effective amount of L-ergothioneine, an analog or derivative thereof, or a pharmaceutically acceptable salt, acid, ester, polymer, analog or derivative thereof, as an active ingredient. In particular, L-ergothioneine is capable of scavenging chronic reactive oxygen species directly and radically to mitigate and prevent HA depolymerization and HA decreasing-viscosity in the mammal's vitreous body; and/or improving vitreous liquefaction in the mammal.
    Type: Application
    Filed: December 20, 2023
    Publication date: April 18, 2024
    Inventors: Ronghua YI, Qiru FAN, Mingru WANG, Ou WANG, Kylin LIAO
  • Publication number: 20240122901
    Abstract: Provided herein are aqueous pharmaceutical compositions of nitrofurantoin for oral administration containing nitrofurantoin as the active pharmaceutical ingredient and one more excipient selected from suspending agents, binders, preservatives, vehicles, sweetening agents, buffering agents and taste masking agents.
    Type: Application
    Filed: October 11, 2022
    Publication date: April 18, 2024
    Inventor: Vimal KAVURU
  • Publication number: 20240122902
    Abstract: According to the invention there is provided a method of improving (e.g. restoring) function in a patient having idiopathic pulmonary fibrosis, which method comprises perorally administering a therapeutically-effective amount of N-butyloxycarbonyl-3-(4-imidazol-1-ylmethylphenyl)-5-iso-butylthiophene-2-sulfonamide (C21), or a pharmaceutically acceptable salt thereof, to said patient. Said treatment is capable of treating said IPF in a therapeutic, including a curative, fashion.
    Type: Application
    Filed: December 20, 2023
    Publication date: April 18, 2024
    Inventors: Carl-Johan DALSGAARD, Rohit BATTA
  • Publication number: 20240122903
    Abstract: Provided herein are methods of treating a subject, such as a subject that has cancer, that include administering a therapeutically effective amount of a STING antagonist or a pharmaceutically acceptable salt, solvate, or co-crystal thereof to a subject identified as having: (I) a cancer cell having one or both of (i) decreased TREX1 level and/or activity, and (ii) increased cGAS/STING signaling pathway activity, e.g., as compared to a reference level, and/or (II) an elevated level of cGAMP in a serum or tumor sample obtained from the subject, e.g., as compared to a reference level.
    Type: Application
    Filed: December 21, 2021
    Publication date: April 18, 2024
    Inventors: Gary Glick, Anthony William Opipari, Jr., Hans Martin Seidel
  • Publication number: 20240122904
    Abstract: The present invention relates to method of modulating TIGIT signaling pathway and PD-1 signaling pathway. The invention also encompasses the use of the compound of formula (I) or a stereoisomer thereof or a pharmaceutically acceptable salt thereof for the treatment of diseases or disorders mediated by both TIGIT signaling pathway and PD-1 signaling pathway.
    Type: Application
    Filed: November 22, 2023
    Publication date: April 18, 2024
    Inventors: Pottayil Govindan Nair SASIKUMAR, Muralidhara RAMACHANDRA, Seetharamaiah Setty Sudarshan NAREMADDEPALLI, Chennakrishnareddy GUNDALA
  • Publication number: 20240122905
    Abstract: The present invention provides a pharmaceutical composition comprising (a) a triblock copolymer having the formula: PLAv-PEGw-PLAx wherein v and x are the number of repeat units ranging from 1 to 3,000 and w is the number of repeat units ranging from 3 to 300 and v=x or v?x in an amount of 22 to 34 w/w % of the total composition; (b) a diblock copolymer having the formula: mPEGy-PLAz wherein y and z are the number of repeat units with y ranging from 2 to 250 and z ranging from 1 to 3,000 in an amount of 5 to 9 w/w % of the total composition; (c) tacrolimus or a pharmaceutically acceptable salt, hydrate or solvate thereof in an amount of 8 to 32 w/w % of the total composition; and (d) organic solvent in an amount of 30 to 62 w/w % of the total composition.
    Type: Application
    Filed: December 15, 2021
    Publication date: April 18, 2024
    Inventors: Maria Dimitrova Ferrand, Julien Bobichon, Vincent Lahaye
  • Publication number: 20240122906
    Abstract: The present disclosure relates to methods of treating melanoma in a patient in need thereof, comprising administering to the subject a therapeutically effective amount of ripretinib or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: November 9, 2023
    Publication date: April 18, 2024
    Inventors: Ying Su, Rodrigo Ruiz Soto
  • Publication number: 20240122907
    Abstract: Provided herein are low impurity compositions comprising a compound represented by Formula (I): which are useful in the treatment of disorders related to the activity of the c-KIT and PDGFR? kinases, and oncogenic forms thereof
    Type: Application
    Filed: November 22, 2023
    Publication date: April 18, 2024
    Inventors: Michael D. Kaufman, Scott Bone, Corey Bloom, Fred Jordan
  • Publication number: 20240122908
    Abstract: Compositions suitable for oral use (e.g., oral thin film) containing various excipients and a combination of melatonin, caryophyllene, GABA, L-theanine, and vitamin B6. Methods of using the composition, e.g., in the treatment of a sleeping disorder, as well as methods of manufacturing the composition are also included.
    Type: Application
    Filed: December 21, 2023
    Publication date: April 18, 2024
    Inventor: Jose Bernardo
  • Publication number: 20240122909
    Abstract: The present invention relates to treatments of hereditary angioedema (HAE). In particular, the present invention provides on-demand treatments of hereditary angioedema (HAE) by orally administering a plasma kallikrein inhibitor to a patient in need thereof on-demand.
    Type: Application
    Filed: February 9, 2022
    Publication date: April 18, 2024
    Inventors: Edward Paul FEENER, Sally Louise MARSH, Andreas MAETZEL, Michael David SMITH, Christopher Martyn YEA
  • Publication number: 20240122910
    Abstract: Provided herein are solid forms comprising {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions comprising the solid forms, methods of making the solid forms and methods of their use for the treatment of various diseases and/or disorders.
    Type: Application
    Filed: May 17, 2023
    Publication date: April 18, 2024
    Inventors: James Densmore Copp, Ann W. Newman, Anne Luong
  • Publication number: 20240122911
    Abstract: Provided are methods for treatment of Fabry disease in patients having HEK assay amenable mutations in ?-galactosidase A. Certain methods comprise administering migalastat or a salt thereof every other day, such as administering about 150 mg of migalastat hydrochloride every other day.
    Type: Application
    Filed: May 31, 2023
    Publication date: April 18, 2024
    Applicant: Amicus Therapeutics, Inc.
    Inventors: Jeff Castelli, Elfrida Benjamin
  • Publication number: 20240122912
    Abstract: The present invention describes the development of a novel, tumor epithelial cell and tumor-associated macrophage (TAM)-targeting, blood brain barrier (BBB) crossing glucose-based nanospheres (CSP). More specifically, the present invention discloses a nanoformulation and/or a composition having anticancer activity comprising of carbon nanosphere (CSP) and a sigma receptor targeting ligand (H8) in the ratio of 1:0.08 to 1:0.2, a complex prepared thereof, a process for preparation thereof and a kit for delivery of the drug molecule or the formulation or the composition to tumor site.
    Type: Application
    Filed: March 29, 2022
    Publication date: April 18, 2024
    Inventors: Madhan Mohan Chandra Sekhar JAGGARAPU, Eswaramoorthy MUTHUSAMY, Tapas Kamar KUNDU, Rajkumar BANERJEE
  • Publication number: 20240122913
    Abstract: Described herein are neurotrophic and nootropic compositions and methods for treating subjects with such compositions. In one aspect the composition comprises one or more tryptamines or in pure form or extracts from psilocybin containing mushrooms, or combinations thereof optionally combined with one or more phenethylamines or amphetamines in pure form or extracts from a plant or mushroom, or combinations thereof, optionally one or more erinacines or hericenones in pure form, extracts from Hericium mushroom species (e.g., H. erinaceus, H. coralloides, H. ramosum) or combinations thereof, optionally one or more cannabinoids in pure form or extracts from Cannabis sativa, Cannabis sativa, Cannabis indica, or Cannabis ruderalis, optionally, one or more adversive compounds, and optionally one or more pharmaceutically acceptable excipients.
    Type: Application
    Filed: December 6, 2023
    Publication date: April 18, 2024
    Inventor: Paul Edward STAMETS
  • Publication number: 20240122914
    Abstract: Described herein are neurotrophic and nootropic compositions and methods for treating subjects with such compositions. In one aspect the composition comprises one or more tryptamines or in pure form or extracts from psilocybin containing mushrooms, or combinations thereof optionally combined with one or more phenethylamines or amphetamines in pure form or extracts from a plant or mushroom, or combinations thereof, optionally one or more erinacines or hericenones in pure form, extracts from Hericium mushroom species (e.g., H. erinaceus, H. coralloides, H. ramosum) or combinations thereof, optionally one or more cannabinoids in pure form or extracts from Cannabis sativa, Cannabis sativa, Cannabis indica, or Cannabis ruderalis, optionally, one or more adversive compounds, and optionally one or more pharmaceutically acceptable excipients.
    Type: Application
    Filed: December 6, 2023
    Publication date: April 18, 2024
    Inventor: Paul Edward STAMETS
  • Publication number: 20240122915
    Abstract: The present invention concerns a combination comprising tasquinimod, or a pharmaceutically acceptable salt thereof, and a PD-1 and/or PD-L1 inhibitor, for use as a medicament. It also concerns a pharmaceutical composition comprising tasquinimod, or a pharmaceutically acceptable salt thereof, and PD-1 and/or PD-L1 inhibitor.
    Type: Application
    Filed: May 11, 2023
    Publication date: April 18, 2024
    Applicant: ACTIVE BIOTECH AB
    Inventors: Jose Amauri SOARES, Eric CHETAILLE, Jessica NAKHLE, Fabien SCHMIDLIN
  • Publication number: 20240122916
    Abstract: A preparation comprising the YEL002 compound as an active ingredient for the prevention or treatment of one or more diseases, and methods of using such preparations. The preparations may be a sublingual pill, an injection, dissolved in liquid, dissolved in oil, or any other preparation. The conditions or diseases indicated may be poisoning, radiation poisoning, chemotherapy poisoning, poor vision, peripheral artery disease, smoker's leg, diabetic feet, periodontal disease, varicose or spider veins, blood clots, COVID-19, long COVID, liver disease, symptoms caused by chemotherapy or radiation therapy, hair loss, cancer, inflammation-caused or inflammation-related diseases, autoimmune diseases, infections, and headaches including migraines.
    Type: Application
    Filed: October 8, 2022
    Publication date: April 18, 2024
    Inventor: Robert H. Schiestl
  • Publication number: 20240122917
    Abstract: Disclosed is the use of a composition containing cilostazol or a pharmaceutically acceptable salt thereof and edaravone in the preparation of a drug for treating cerebrovascular diseases, especially ischemic cerebrovascular diseases. The experiment result shows that the tail vein administration of 1-15 mg/kg of cilostazol or 1.67-8.33 mg/kg of edaravone on rats with a focal cerebral ischemia-reperfusion injury can significantly ameliorate neurological defects in rats with an MCAO and reduce a cerebral infarction area; and performing compound combination within the dosage range (the mass ratio of cilostazol:edaravone is 1:5 to 5:1) can be synergistic. The tail vein administration of 3.33-16.67 mg/kg of cilostazol or 3.33-16.67 mg/kg of edaravone on mice with a focal cerebral ischemia-reperfusion injury can significantly ameliorate neurological defects in mice with an MCAO and reduce a cerebral infarction area.
    Type: Application
    Filed: January 26, 2022
    Publication date: April 18, 2024
    Applicant: NEURODAWN PHARMACEUTICAL CO., LTD.
    Inventors: Yao HUA, Lei WANG, Zhengping ZHANG, Rong CHEN, Shibao YANG
  • Publication number: 20240122918
    Abstract: A drug delivery device comprising: a first layer comprising a first coaxially electrospun nanofiber membrane; a second layer comprising a second coaxially electrospun nanofiber membrane; a first therapeutic agent integrated into the first coaxially electrospun nanofiber membrane; and a second therapeutic agent integrated into the second coaxially electrospun nanofiber membrane. The second therapeutic agent is different from the first therapeutic agent.
    Type: Application
    Filed: October 17, 2023
    Publication date: April 18, 2024
    Inventors: Andrew Steckl, Daewoo Han, Betty M. Tyler, Henry Brem, Safwan Alomari
  • Publication number: 20240122919
    Abstract: The present invention provides a method of treating depression disease in a treatment resistant patient comprising administering to a mucosal membrane of a patient an effective amount of a pharmaceutically acceptable composition comprising an effective amount of ketamine or dextromethorphan, wherein the mucosal administration of the ketamine or dextromethorphan containing composition allows for the mucosal absorption of the composition eliminating the digestive tract of the patient for effecting a rapid acting antidepressant treatment of the treatment resistant patient. This method includes administering the composition to a patient's mucosal membrane of a respiratory tract, a genitourinary tract, an oral tract, or rectal tract of the patient. A pharmaceutically acceptable composition comprising ketamine or dextromethorphan and a vehicle is disclosed. A biomarker for identifying a depressive disease is set forth.
    Type: Application
    Filed: December 22, 2023
    Publication date: April 18, 2024
    Inventors: Scott Pollard, Patrick Marshalek, Rae Matsumoto
  • Publication number: 20240122920
    Abstract: The present disclosure relates to cured pharmaceutical compositions designed to reduce the potential for improper administration of drugs that are subject to abuse, the process of curing such composition in order to improve the dissolution stability, method of using the same for treatment of pain.
    Type: Application
    Filed: December 22, 2023
    Publication date: April 18, 2024
    Inventors: Said SAIM, Alison B. FLEMING, Ravi K. VARANASI
  • Publication number: 20240122921
    Abstract: The present invention relates to methods for treating patients with cancer, including patients with hematological malignancy, wherein the method comprises administering to the patient a therapeutically effective amount of a compound of formula (I), or a pharmaceutically acceptable salt thereof, wherein R1 and R2 are as defined herein.
    Type: Application
    Filed: September 25, 2023
    Publication date: April 18, 2024
    Inventors: Yifan ZHAI, Zi CHEN, Qian JIANG, Xiaojun HUANG, Wei LIU, Dajun YANG
  • Publication number: 20240122922
    Abstract: Compositions comprising a TMEM16F inhibitor, an anti-cancer agent, and a pharmaceutically acceptable agent, and methods of treating of cancer comprising administering a TMEM16F inhibitor are provided herein.
    Type: Application
    Filed: September 25, 2023
    Publication date: April 18, 2024
    Inventors: Igor Astsaturov, Edna Cukierman
  • Publication number: 20240122923
    Abstract: The present disclosure is directed to methods for treating hidradenitis suppurativa (HS) using the selective JAK1 inhibitor upadacitinib.
    Type: Application
    Filed: September 28, 2023
    Publication date: April 18, 2024
    Inventors: Aileen L. PANGAN, Mohamed-Eslam F. Mohamed
  • Publication number: 20240122924
    Abstract: The disclosure provides methods the treatment of psychiatric disorders caused by viral, bacterial, or autoimmune encephalitis, and for treatment of psychiatric symptoms of viral, bacterial, and autoimmune encephalitis, and for protecting or reinforcing the blood-brain barrier, comprising administering to a patient in need thereof, a therapeutically effective amount of a 5-HT2A.
    Type: Application
    Filed: November 22, 2023
    Publication date: April 18, 2024
    Inventors: Sophie DUTHEIL, Gretchen SNYDER, Peng LI, Robert E. DAVIS
  • Publication number: 20240122925
    Abstract: The disclosure is in part directed to crystalline forms of (R)-1?-(3-(3,4-dihydro-1,5-naphthyridin-1(2H)-yl)-1H-pyrazolo[3,4-b]pyrazin-6-yl)-3H-spiro[benzofuran-2,4?-piperidin]-3-amine, its salt, and variants thereof.
    Type: Application
    Filed: December 19, 2023
    Publication date: April 18, 2024
    Inventors: Alexander M. Taylor, André Lescarbeau, Jing Wang, Yanyan Zhang, Gaodeng Lian
  • Publication number: 20240122926
    Abstract: Apelin receptor modulators can improve physical performance, slow progression of age-related frailty, and can reduce age-related muscle weakness in human patients. This disclosure provides methods for treating muscle conditions using a particular class of apelin receptor modulators (e.g., agonists). The muscle condition can be an age-related muscle condition. Also provided is a method for maintaining and/or increasing muscle mass, muscle function, and/or muscle strength in an elderly subject by administration of the apelin receptor modulator. In some embodiments, the apelin receptor modulator (e.g., agonist) is BGE-105, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: September 27, 2023
    Publication date: April 18, 2024
    Inventors: Kristen Patricia FORTNEY, Eric Kim MORGEN, Justin REBO, Robert HUGHES, Fred ASWAD, Peng Khun LEONG, Sashanaz H. IGDARI, Paul David RUBIN, Rusty Lee MONTGOMERY
  • Publication number: 20240122927
    Abstract: The present disclosure generally relates to methods of treating hemolytic diseases such as sickle cell anemia using kinase inhibitors, for example, compounds that inhibit the spleen tyrosine kinase (SYK). In some embodiments a method is presented to prevent thrombosis in blood vessels of patients with a hemolytic disease comprising the step of: administrating to a patient having at least one hemolytic disease a therapeutically effective amount of at least one SYK inhibitor. In some embodiments the method includes repeatedly administering the SYK kinase inhibitor to a patient.
    Type: Application
    Filed: December 5, 2023
    Publication date: April 18, 2024
    Inventors: Philip Stewart Low, Francesco Turrini, Antonella Pantaleo
  • Publication number: 20240122928
    Abstract: The present invention relates to a method of treating agitation in a human patient with dementia, comprising administering to the human patient with dementia in need thereof a pharmaceutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt or hydrate thereof to treat agitation, wherein R1-R4 are defined herein: wherein the human patient has at least an about 20% reduction in their symptom of agitation, relative to the patient prior to administration of the compound of formula (I).
    Type: Application
    Filed: December 5, 2023
    Publication date: April 18, 2024
    Inventors: Wayne Drevets, Pascal Bonaventure, Gahan Pandina
  • Publication number: 20240122929
    Abstract: A body temperature lowering agent, a body temperature elevation suppressor, a food composition for lowering body temperature, and a food composition for suppressing body temperature elevation containing at least one substance selected from the group consisting of orotic acid, a derivative thereof, and a salt of the orotic acid or the derivative as an active ingredient.
    Type: Application
    Filed: February 14, 2022
    Publication date: April 18, 2024
    Inventors: Hideaki SOYA, Takuya SHIBASAKI
  • Publication number: 20240122930
    Abstract: The invention relates to methods of (i) treating a subject for a disease, (ii) amelioration of decline of forced vital capacity in a subject in need thereof, (iii) modulating ?V?6 integrin, ?V?1 integrin, or both ?V?6 integrin and ?V?1 integrin in a subject in need thereof, (iv) increasing the expression of one or more genes in a subject in need thereof, (v) decreasing the expression of one or more genes in a subject in need thereof, and (vi) modulating the activity of at least one gene affecting fibrotic activity in a subject in need thereof, comprising administration of compounds of Formula (A), Formula (I), Formula (II), or (S)-4-((2-methoxyethyl)(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl)amino)-2-(quinazolin-4-ylamino)butanoic acid, or a pharmaceutically acceptable salt thereof as described herein; and administering to the subject at least a second drug selected from pirfenidone and nintedanib, or a salt thereof.
    Type: Application
    Filed: July 7, 2023
    Publication date: April 18, 2024
    Inventors: Eric LEFEBVRE, Gregory P. COSGROVE, Scott TURNER, Martin L. DECARIS, Johanna Roberta SCHAUB
  • Publication number: 20240122931
    Abstract: The invention features methods of treating a SARS-CoV-2 infection in a subject, the method comprising administering to the subject an effective amount of sepiapterin or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: February 9, 2022
    Publication date: April 18, 2024
    Inventors: Gene Chatman CLARK, Eleonora MEZZAROMA, Christopher RABENDER, Ross B. MIKKELSEN, Vasily YAKOVLEV, Neil SMITH
  • Publication number: 20240122932
    Abstract: The present disclosure provides methods of treating B-cell malignancy in a subject with a Bcl-2 inhibitor, in particularly 2-((1H-pyrrolo[2,3-b]pyridin-5-yl)oxy)-N-((4-((((1r,4r)-4-hydroxy-4-methylcyclohexyl)methyl)amino)-3-nitrophenyl)sulfonyl)-4-(2-((S)-2-(2-isopropylphenyl)pyrrolidin-1-yl)-7-azaspiro[3.5]nonan-7-yl)benzamide or a pharmaceutically acceptable salt thereof, or its combination with a Bruton's tyrosine kinase (BTK) inhibitor, particularly (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetrahydropyrazolo-[1,5-a]pyrimidine-3-carboxamide or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: November 30, 2023
    Publication date: April 18, 2024
    Applicant: BeiGene Switzerland GmbH
    Inventors: James D. Hilger, Jane Huang, David Simpson
  • Publication number: 20240122933
    Abstract: Compositions comprising an isoquinoline-1,5-diamine BRaf inhibitor and optionally an additional therapeutic agent are provided, also disclosed are methods of treatment, healing, and/or amelioration of wounds by topical administration of a therapeutically effective amount of the composition of this invention to a wound in a subject in need thereof.
    Type: Application
    Filed: December 8, 2023
    Publication date: April 18, 2024
    Inventor: Noa Shelach
  • Publication number: 20240122934
    Abstract: Compositions and methods of treatment for inhibiting capillary tube regression and/or lymphatic tube regression are described, as well as factors and signaling pathways that control the regression of capillary tube networks. Capillary tube regression and/or lymphatic tube regression may be implicated in ischemia, infarction, hypertension, diabetes, malignant cancer, neurodegenerative disease, wound repair response, atherosclerosis, pro-inflammatory disease, pro-thrombotic disease, viral infection (e.g., influenza or SARS-CoV-2), bacterial infection.
    Type: Application
    Filed: October 16, 2020
    Publication date: April 18, 2024
    Inventors: George E. Davis, Gretchen Margaret Koller